Australia - English - Department of Health (Therapeutic Goods Administration)

orpharma pty ltd - nitisinone, quantity: 5 mg - tablet - excipient ingredients: lactose monohydrate; glycerol dibehenate - nityr tablets (nitisinone) are indicated for the treatment of patients with hereditary tyrosinaemia type 1 in combination with dietary restriction of tyrosine and phenylalanine.

Australia - English - Department of Health (Therapeutic Goods Administration)

orpharma pty ltd - nitisinone, quantity: 2 mg - tablet - excipient ingredients: lactose monohydrate; glycerol dibehenate - nityr tablets (nitisinone) are indicated for the treatment of patients with hereditary tyrosinaemia type 1 in combination with dietary restriction of tyrosine and phenylalanine.

Australia - English - Department of Health (Therapeutic Goods Administration)

orpharma pty ltd - nitisinone, quantity: 10 mg - tablet - excipient ingredients: lactose monohydrate; glycerol dibehenate - nityr tablets (nitisinone) are indicated for the treatment of patients with hereditary tyrosinaemia type 1 in combination with dietary restriction of tyrosine and phenylalanine.

Australia - English - Department of Health (Therapeutic Goods Administration)

dr falk pharma australia pty ltd - mesalazine, quantity: 1 g - tablet, enteric coated - excipient ingredients: povidone; microcrystalline cellulose; croscarmellose sodium; colloidal anhydrous silica; calcium stearate; hypromellose; methacrylic acid copolymer; purified talc; titanium dioxide; iron oxide yellow; macrogol 6000 - salofalk tablets are indicated in the treatment of acute episodes and maintenance of remission of: i. mild to moderate ulcerative colitis; and ii. crohn?s ileitis and colitis

Australia - English - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - estradiol valerate, quantity: 2 mg - tablet, sugar coated - excipient ingredients: magnesium stearate; macrogol 6000; sucrose; glycol montanate; calcium carbonate; povidone; maize starch; lactose monohydrate; purified talc - indications as at 19 july 2004: short term treatment of climacteric complaints after the cessation of monthly bleeding, or deficiency symptoms after oophorectomy or radiological castration for non-carcinomatous diseases, such as hot flushes, outbreaks of sweat, sleep disturbances, depressive moods, irritability, headaches, dizziness. progynova has also a favourable influence on bladder irritation (a not infrequent occurrence in the climacteric), signs of cutaneous and mucosal involution (particularly in the genital region) which normally occur with advancing age.

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - estriol, quantity: 1 mg - tablet, uncoated - excipient ingredients: amylopectin; potato starch; lactose monohydrate; magnesium stearate - short-term treatment of menopausal syndrome. review the need for continuation of treatment after 6 months treatment, taking into account the risk-benefit ratio for the individual user at that moment (including cardiovascular disease and breast cancer, refer to clinical trials and precautions). ovestin tablets should only be continued for as long as the benefit outweighs the risks.

Singapore - English - HSA (Health Sciences Authority)

abbott laboratories (singapore ) private limited - dydrogesterone, micronized (in grey tablet); estradiol hemihydrate 1.03 mg eqv estradiol (micronised) (in grey tablet); estradiol hemihydrate 1.03 mg eqv estradiol (micronised) (in white tablet) - tablet, film coated - 10 mg - dydrogesterone, micronized (in grey tablet) 10 mg; estradiol hemihydrate 1.03 mg eqv estradiol (micronised) (in grey tablet) 1 mg; estradiol hemihydrate 1.03 mg eqv estradiol (micronised) (in white tablet) 1 mg

Australia - English - Department of Health (Therapeutic Goods Administration)

micro labs pty ltd - amoxicillin trihydrate, quantity: 1004.31 mg; potassium clavulanate, quantity: 151.917 mg - tablet, film coated - excipient ingredients: magnesium stearate; colloidal anhydrous silica; dichloromethane; microcrystalline cellulose; sodium starch glycollate; isopropyl alcohol; titanium dioxide; hypromellose; propylene glycol; purified talc; ethylcellulose - amclavox duo forte 875/125 tablets are indicated for short-term treatment of bacterial infections at the following sites when caused by sensitive organisms (refer to microbiology):,urinary tract infections (complicated and uncomplicated),lower respiratory tract infections, including community acquired pneumonia and acute exacerbations of chronic bronchitis,upper respiratory tract infections, such as sinusitis, otitis media and recurrent tonsillitis.,skin and skin structure infection.,appropriate culture and susceptibility studies should be performed to identify the causative organism(s) and determine its (their) susceptibility to amoxicillin and clavulanic acid tablets. however, when there is reason to believe an infection may involve any of the beta-lactamase producing organisms listed above, therapy may be instituted prior to obtaining the results from bacteriological and susceptibility studies. once these results are known, therapy should be adjusted if appropriate. the treatment of mixed infections caused by amoxicillin susceptible organisms and beta-lactamase producing organisms susceptible to amoxicillin and clavulanic acid tablets preparations should not require the addition of another antibiotic due to the amoxicillin content of these products.

Australia - English - Department of Health (Therapeutic Goods Administration)

micro labs pty ltd - potassium clavulanate, quantity: 151.917 mg; amoxicillin trihydrate, quantity: 573.892 mg - tablet, film coated - excipient ingredients: colloidal anhydrous silica; magnesium stearate; microcrystalline cellulose; dichloromethane; isopropyl alcohol; sodium starch glycollate; titanium dioxide; hypromellose; propylene glycol; purified talc; ethylcellulose - amclavox duo 500/125 tablets are indicated for short-term treatment of bacterial infections at the following sites when caused by sensitive organisms (refer to microbiology):,urinary tract infections (complicated and uncomplicated),lower respiratory tract infections, including community acquired pneumonia and acute exacerbations of chronic bronchitis,upper respiratory tract infections, such as sinusitis, otitis media and recurrent tonsillitis.,skin and skin structure infection.,appropriate culture and susceptibility studies should be performed to identify the causative organism(s) and determine its (their) susceptibility to amoxicillin and clavulanic acid tablets. however, when there is reason to believe an infection may involve any of the beta-lactamase producing organisms listed above, therapy may be instituted prior to obtaining the results from bacteriological and susceptibility studies. once these results are known, therapy should be adjusted if appropriate. the treatment of mixed infections caused by amoxicillin susceptible organisms and beta-lactamase producing organisms susceptible to amoxicillin and clavulanic acid tablets preparations should not require the addition of another antibiotic due to the amoxicillin content of these products.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - amoxicillin trihydrate, quantity: 1004.31 mg; potassium clavulanate, quantity: 151.917 mg - tablet, film coated - excipient ingredients: magnesium stearate; colloidal anhydrous silica; dichloromethane; microcrystalline cellulose; sodium starch glycollate; isopropyl alcohol; titanium dioxide; hypromellose; propylene glycol; purified talc; ethylcellulose - amclavox duo forte 875/125 tablets are indicated for short-term treatment of bacterial infections at the following sites when caused by sensitive organisms (refer to microbiology):,urinary tract infections (complicated and uncomplicated),lower respiratory tract infections, including community acquired pneumonia and acute exacerbations of chronic bronchitis,upper respiratory tract infections, such as sinusitis, otitis media and recurrent tonsillitis.,skin and skin structure infection.,appropriate culture and susceptibility studies should be performed to identify the causative organism(s) and determine its (their) susceptibility to amoxicillin and clavulanic acid tablets. however, when there is reason to believe an infection may involve any of the beta-lactamase producing organisms listed above, therapy may be instituted prior to obtaining the results from bacteriological and susceptibility studies. once these results are known, therapy should be adjusted if appropriate. the treatment of mixed infections caused by amoxicillin susceptible organisms and beta-lactamase producing organisms susceptible to amoxicillin and clavulanic acid tablets preparations should not require the addition of another antibiotic due to the amoxicillin content of these products.